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(NOACs), 5.2% on antiplatelets (AP) and 11.0% on VKA+AP combinations. In the 
“convenience” dimension, the overall score (0-100 range) was 82.9 ±17.3. The score 
was higher in the NOAC group (88.1 ± 13.0) compared to the VKA (82.1 ± 17.5), AP (87.0 
± 17.9) or VKA +AP groups (83.2 ± 16.8), respectively. In the “anticoagulant treatment 
satisfaction” dimension of the PACT-Q2, the overall score was 63.4 ±15.9. Again, 
this score was higher in the NOAC group (66.6 ±16.6) compared to the VKA (63.2 
±15.9), AP (63.7 ±16.8), or VKA + AP groups (62.8 ±15.0), respectively. ConClusions: 
Overall, patients on current anticoagulation achieve relatively high values on the 
convenience scale, but moderate values on the satisfaction scale. While differences 
in group size and patient characteristics need to be taken into account, patients 
on NOACs compared to patients on VKAs tend to rate their convenience and treat-
ment satisfaction higher.
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objeCtives: Aim of the study was to investigate whether chronic patients are 
willing to pay an extra amount of money in order to switch to another drug that it 
is either on patent, more effective or simpler in dose. Methods: A cross-sectional 
study was conducted among 1600 chronic patients suffering from diabetes, hyper-
tension, COPD and Alzheimer. Logistic regression analysis was carried out to explore 
the factors that influence patients’ decision on willingness to pay (WTP) for an 
alternative drug with innovative characteristics. Results: Of the 1600 patients 
approached, 1594 responded to the survey (99.6%). A total of 40% stated that they 
would be willing to pay more for a patent drug, 57.5% for a more effective drug and 
37.5% for a simpler in dose drug. The average additional amount per month that 
they would be willing to spend was estimated at 23.6€ for a patent drug, 24.1€ for a 
more effective drug and 21.9€ for a simpler in dose drug. Statistical analysis revealed 
that WTP for a patent drug was statistically significant related with the patient’s 
income (OR,1.24;95%CI, 1.14-1.34) while WTP for a more effective or a simpler in dose 
drug was positively related with the patient’s income (OR,1.25;95%CI, 1,13-1,39 and 
OR, 1,14;95%CI, 1.05-1.24 respectively) and educational level (OR,1.06;95%CI, 1,01-
1.13 and OR, 1.06;95%CI, 1.01-1.13, respectively). ConClusions: Half of chronic 
patients demonstrate absolute willingness to increase spending for an innovative 
drug, which highlights the significance they attribute to pharmaceuticals for the 
management of their condition. The remaining’s 50% reluctance may be attributed 
to the extended trust on their current pharmaceutical treatment and to the efforts 
and money spent in order to control their condition. However, patients with higher 
socioeconomic status are more likely to express WTP which reflects the economic 
burden imposed by chronic conditions, and the role of education in shaping patient 
attitudes.
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objeCtives: Identification of differences in the length of hospital stay for patients 
with atrial fibrillation (AF) with and without oral anticoagulation (OA). Longer 
stays of patients could lead to an economical burden for the hospital because 
of the Diagnosis Related Groups (DRG) system in Germany and the compensa-
tion with case-based lump sum. Methods: We conducted a retrospective study 
using an electronic DRG benchmarking database. This database contains DRG 
data from 208 hospitals in Germany with over 2,800,000 inpatient cases per year. 
In total, 10,912,922 cases from the year 2010 to 2012 were analyzed. 661,845 cases 
fulfilled the inclusion criteria and were analyzed according the statistical analy-
sis plan including matched pair analyses. Results: Cases with AF and surgical 
intervention compared to cases without AF and with surgical intervention have 
a significantly longer pre-operation length of stay (+0.74 days) and a significantly 
longer hospital stay (+1.5 days). Furthermore cases with chronic AF (= AF+OA) 
have a significantly longer total length of stay in the hospital (+0.86 days). For 
the cases with AF and bleeding vs. cases without bleeding, there is no significant 
difference in the total length of stay, but there is a significantly longer stay of 0.82 
days compared to the average length of stay in the DRG-catalogue. ConClusions: 
Patients with AF and with or without OA could be an economic burden for the 
hospital, because the increased length of stay in hospital leads to higher costs 
whereas the existing compensation diagnosis-based lump sum is not affected by 
increased treatment days. The new oral anticoagulants could lead to shorter stays 
of patients with AF by shortening the bridging periods compared to OA like vitamin 
K antagonists. Further studies should be conducted to figure out the causes for 
longer hospital stays of patients with AF.
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patients with diabetes, HRQoL was lower across all health dimensions measured 
by the EQ-5D; except mobility and self-care. Individualised therapeutic manage-
ment programs could be considered in order to improve the HRQoL of CAD patients 
with diabetes.
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objeCtives: Patient Perception of Arrhythmia Questionnaire (PPAQ) is a disease-
specific questionnaire designed to measure symptoms and health-related quality of 
life in patients suffering from a group of arrhythmias collectively called supraven-
tricular tachycardias (SVT). There is no valid translation of PPAQ available in Poland, 
which hinders research in this area with Polish arrhythmia patients. The aim of 
this study was to conduct initial content validity testing through translation and 
cultural adaptation of the English language version of the PPAQ to the Polish lan-
guage. Methods: The whole project was conducted according to ISPOR Principles 
of Good Practice for the Translation and Cultural Adaptation Process for Patient-
Reported Outcomes (PRO) Measures published in 2005. Results: In 2011, the PPAQ 
was translated into Polish and cultural adaptation was performed on 20 patients 
with SVT (12 male, age 54.9±17.4). Issues concerning close meanings of symptom 
names and language-dependant gender-related distinctions were identified. The 
former was solved by cooperation with experts in arrhythmia and latter by incor-
porating patients’ preferences during cognitive debriefing. ConClusions: The 
Polish translation was well accepted by patients during this translation and initial 
content validity testing. Issues arisen during the translation process may recur in 
other translations and be resolved in similar manner.
PCV138
health-relateD Quality of life in Patients along first year 
Poststroke in sPain
Álvarez Sabín J.1, Masjuan J.2, Torres C.3, Mar J.4, Oliva J.5, González-Rojas N.6
1Hospital Vall D’Hebrón, Barcelona, Spain, 2Hospital Ramón y Cajal, Madrid, Spain, 
3Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 4Hospital Alto Deba, 
Mondragon, Spain, 5Castilla-La Mancha University, Toledo, Spain, 6Boehringer Ingelheim, Sant 
Cugat del Vallès (Barcelona), Spain
objeCtives: Atrial fibrillation (AF) 5-folds stroke risk, which results in death or dis-
ability in 80% of individuals and one-year mortality approaches 50%. The objective of 
the present study was to analyze the health-related quality of live (HRQoL) one year 
post-stroke in patients with or without AF and the burden of caregivers. Methods: 
We performed an observational, multicenter, naturalistic and prospective study that 
included 16 stroke units from different Spanish regions. We used EQ-5D and VAS to 
test patients HRQoL and Zarit Burden Inventory to estimate the caregiver burden. 
We collected information at hospital entry for patients, 3 and 12 months post-
stroke both for patients and carers through direct physician interviews. Results: 
A total of 321 stroke patients were recruited, 160 with and 161 without AF. EQ-5D 
was completed by 274 patients - 127 with AF and 147 without AF -, and VAS by 249 
- 113 with and 136 without AF -. The average utility scores of EQ-5D were 0.57, 0.62, 
and 0.65. We found a statistically significant difference between AF and non-AF 
obtained at hospital entry (p= 0.029) and 12 months post-stroke (p= 0.023). There 
were no differences between hospital visits (p= 0.112). If we took into consideration 
the age of patients, the absence or presence of AF in EQ-5D scores, lost its signifi-
cance (p= 0.099). VAS average scores were 45.81, 44.15 and 45.74. VAS results showed 
non-significant differences neither by AF presence (p= 0.396) nor time (p= 0.613). 
Caregiver burden was higher in AF than non-AF patientes (46.47 vs 40.93 2nd visit 
and 45.29 vs 38.73 3rd visit) and the difference was statistically significant (p= 0.007 
and p= 0.002). ConClusions: Stroke has a deep impact on patients HRQoL with 
no improvement over time. In the same line, caregivers also support an important 
burden related to stroke and specially in AF patients.
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objeCtives: The great majority of patients with atrial fibrillation (AF) require anti-
coagulation in order to prevent strokes or other thromboembolic events. We aimed 
at obtaining detailed and current information on patients’ satisfaction with their 
ongoing anticoagulation treatment. Methods: PREFER in AF (The PREvention oF 
thromboembolic events – European Registry in Atrial Fibrillation) is a current non-
interventional study performed in France, Germany, Austria, Switzerland, Italy, 
Spain and UK. A total of 7243 consecutive patients with ECG-confirmed AF in the 
previous 12 months are followed up prospectively. The ‘Perception of Anticoagulant 
Treatment Questionnaire’ is a valid and reliable instrument that allows the assess-
ment of patients’ expectations (PACT-Q1) and satisfaction regarding anticoagu-
lant treatment, as well as patients’ opinion about treatment convenience of use 
(PACT-Q2). Results: A total of 5049 patients (69.7%) received antithrombotic treat-
ment and were willing to fill out the PACT-Q2 questionnaire at baseline. 77.1% 
of these were on vitamin K antagonists (VKAs), 6.4% on new oral anticoagulants 
